176 related articles for article (PubMed ID: 24552952)
1. A neutralization assay for chikungunya virus infections in a multiplex format.
Weber C; König R; Niedrig M; Emmerich P; Schnierle BS
J Virol Methods; 2014 Jun; 201():7-12. PubMed ID: 24552952
[TBL] [Abstract][Full Text] [Related]
2. Development of a pseudotyped-lentiviral-vector-based neutralization assay for chikungunya virus infection.
Kishishita N; Takeda N; Anuegoonpipat A; Anantapreecha S
J Clin Microbiol; 2013 May; 51(5):1389-95. PubMed ID: 23408687
[TBL] [Abstract][Full Text] [Related]
3. Development of a neutralization assay based on the pseudotyped chikungunya virus of a Korean isolate.
Chung WC; Hwang KY; Kang SJ; Kim JO; Song MJ
J Microbiol; 2020 Jan; 58(1):46-53. PubMed ID: 31768937
[TBL] [Abstract][Full Text] [Related]
4. Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout.
Gläsker S; Lulla A; Lulla V; Couderc T; Drexler JF; Liljeström P; Lecuit M; Drosten C; Merits A; Kümmerer BM
Virol J; 2013 Jul; 10():235. PubMed ID: 23855906
[TBL] [Abstract][Full Text] [Related]
5. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates.
Mallilankaraman K; Shedlock DJ; Bao H; Kawalekar OU; Fagone P; Ramanathan AA; Ferraro B; Stabenow J; Vijayachari P; Sundaram SG; Muruganandam N; Sarangan G; Srikanth P; Khan AS; Lewis MG; Kim JJ; Sardesai NY; Muthumani K; Weiner DB
PLoS Negl Trop Dis; 2011 Jan; 5(1):e928. PubMed ID: 21264351
[TBL] [Abstract][Full Text] [Related]
6. Curcumin and Boswellia serrata gum resin extract inhibit chikungunya and vesicular stomatitis virus infections in vitro.
von Rhein C; Weidner T; Henß L; Martin J; Weber C; Sliva K; Schnierle BS
Antiviral Res; 2016 Jan; 125():51-7. PubMed ID: 26611396
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV Vaccine.
Henss L; Yue C; Von Rhein C; Tschismarov R; Lewis-Ximenez LL; Dölle A; Baylis SA; Schnierle BS
J Infect Dis; 2020 Apr; 221(10):1713-1723. PubMed ID: 31828322
[TBL] [Abstract][Full Text] [Related]
8. The green tea catechin, epigallocatechin gallate inhibits chikungunya virus infection.
Weber C; Sliva K; von Rhein C; Kümmerer BM; Schnierle BS
Antiviral Res; 2015 Jan; 113():1-3. PubMed ID: 25446334
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Methods for CHIKV Based on Serological Tools.
Gaibani P; Landini MP; Sambri V
Methods Mol Biol; 2016; 1426():63-73. PubMed ID: 27233261
[TBL] [Abstract][Full Text] [Related]
10. Development of Neutralization Assay Using an eGFP Chikungunya Virus.
Deng CL; Liu SQ; Zhou DG; Xu LL; Li XD; Zhang PT; Li PH; Ye HQ; Wei HP; Yuan ZM; Qin CF; Zhang B
Viruses; 2016 Jun; 8(7):. PubMed ID: 27367716
[TBL] [Abstract][Full Text] [Related]
11. Effective chikungunya virus-like particle vaccine produced in insect cells.
Metz SW; Gardner J; Geertsema C; Le TT; Goh L; Vlak JM; Suhrbier A; Pijlman GP
PLoS Negl Trop Dis; 2013; 7(3):e2124. PubMed ID: 23516657
[TBL] [Abstract][Full Text] [Related]
12. Antigenic Variation of East/Central/South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune Sera.
Chua CL; Sam IC; Merits A; Chan YF
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004960. PubMed ID: 27571254
[TBL] [Abstract][Full Text] [Related]
13. A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.
Goo L; Dowd KA; Lin TY; Mascola JR; Graham BS; Ledgerwood JE; Pierson TC
J Infect Dis; 2016 Nov; 214(10):1487-1491. PubMed ID: 27655868
[TBL] [Abstract][Full Text] [Related]
14. Neutralization Assay for Chikungunya Virus Infection: Plaque Reduction Neutralization Test.
Azami NA; Moi ML; Takasaki T
Methods Mol Biol; 2016; 1426():273-82. PubMed ID: 27233280
[TBL] [Abstract][Full Text] [Related]
15. Establishment of an Alphavirus-Specific Neutralization Assay to Distinguish Infections with Different Members of the Semliki Forest complex.
Henss L; Yue C; Kandler J; Faddy HM; Simmons G; Panning M; Lewis-Ximenez LL; Baylis SA; Schnierle BS
Viruses; 2019 Jan; 11(1):. PubMed ID: 30669393
[TBL] [Abstract][Full Text] [Related]
16. Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry.
Henß L; Beck S; Weidner T; Biedenkopf N; Sliva K; Weber C; Becker S; Schnierle BS
Virol J; 2016 Aug; 13(1):149. PubMed ID: 27581733
[TBL] [Abstract][Full Text] [Related]
17. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
Front Immunol; 2020; 11():304. PubMed ID: 32194557
[TBL] [Abstract][Full Text] [Related]
18. Preparation of vesicular stomatitis virus pseudotype with Chikungunya virus envelope protein.
Tong W; Yin XX; Lee BJ; Li YG
Acta Virol; 2015 Jun; 59(2):189-93. PubMed ID: 26104337
[TBL] [Abstract][Full Text] [Related]
19. Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development.
Kam YW; Lee WW; Simarmata D; Le Grand R; Tolou H; Merits A; Roques P; Ng LF
PLoS One; 2014; 9(4):e95647. PubMed ID: 24755730
[TBL] [Abstract][Full Text] [Related]
20. Serological Responses in Patients Infected with Mayaro Virus and Evaluation of Cross-Protective Responses against Chikungunya Virus.
Bopp NE; Jencks KJ; Siles C; Guevara C; Vilcarromero S; Fernández D; Halsey ES; Ampuero JS; Aguilar PV
Am J Trop Med Hyg; 2021 Nov; 106(2):607-609. PubMed ID: 34844213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
